NO300135B1 - Heterocyklisk substituerte 2-acylamino-5-tiazoler, og mellomprodukter for fremstilling derav - Google Patents
Heterocyklisk substituerte 2-acylamino-5-tiazoler, og mellomprodukter for fremstilling derav Download PDFInfo
- Publication number
- NO300135B1 NO300135B1 NO922215A NO922215A NO300135B1 NO 300135 B1 NO300135 B1 NO 300135B1 NO 922215 A NO922215 A NO 922215A NO 922215 A NO922215 A NO 922215A NO 300135 B1 NO300135 B1 NO 300135B1
- Authority
- NO
- Norway
- Prior art keywords
- group
- alkyl
- constitutes
- formula
- phenyl
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title description 13
- 239000000543 intermediate Substances 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 54
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 14
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 8
- 125000005843 halogen group Chemical group 0.000 claims abstract description 6
- 125000002843 carboxylic acid group Chemical group 0.000 claims abstract description 4
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 4
- 125000001424 substituent group Chemical group 0.000 claims abstract description 4
- 150000002367 halogens Chemical class 0.000 claims abstract description 3
- -1 phenyl carbon Chemical compound 0.000 claims description 21
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- 239000000460 chlorine Substances 0.000 claims description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 abstract description 4
- 150000001412 amines Chemical class 0.000 abstract description 3
- 125000004103 aminoalkyl group Chemical group 0.000 abstract description 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000005242 carbamoyl alkyl group Chemical group 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 125000004966 cyanoalkyl group Chemical group 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 86
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 60
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 35
- 239000000203 mixture Substances 0.000 description 35
- 239000000243 solution Substances 0.000 description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 239000012074 organic phase Substances 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 238000000034 method Methods 0.000 description 24
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 21
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 19
- 239000002253 acid Substances 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 229940107137 cholecystokinin Drugs 0.000 description 16
- 101800001982 Cholecystokinin Proteins 0.000 description 15
- 102100025841 Cholecystokinin Human genes 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 14
- 239000011734 sodium Substances 0.000 description 13
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical class C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 239000002585 base Substances 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 9
- 239000003480 eluent Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- KXHBYSRUWPZBMF-UHFFFAOYSA-N 1-acetylindole-2-carboxylic acid Chemical compound C1=CC=C2N(C(=O)C)C(C(O)=O)=CC2=C1 KXHBYSRUWPZBMF-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 8
- 150000003557 thiazoles Chemical class 0.000 description 8
- 102400000921 Gastrin Human genes 0.000 description 7
- 108010052343 Gastrins Proteins 0.000 description 7
- 239000007853 buffer solution Substances 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000010908 decantation Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 108010089335 Cholecystokinin A Receptor Proteins 0.000 description 4
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 description 4
- 102100034927 Cholecystokinin receptor type A Human genes 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000010933 acylation Effects 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- 229950003476 aminothiazole Drugs 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- SYYLBTHATZNOSE-UHFFFAOYSA-N 1-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]indole-2-carboxylic acid Chemical compound C1=CC=C2N(CC(=O)OC(C)(C)C)C(C(O)=O)=CC2=C1 SYYLBTHATZNOSE-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- YUMHQQUMURQNOP-UHFFFAOYSA-N 5-benzyl-4-(2,4-dimethoxyphenyl)-1,3-thiazol-2-amine Chemical compound COC1=CC(OC)=CC=C1C1=C(CC=2C=CC=CC=2)SC(N)=N1 YUMHQQUMURQNOP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 3
- 150000008046 alkali metal hydrides Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000012062 aqueous buffer Substances 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- WOAKYNXITKJPIU-UHFFFAOYSA-N 1-(2-amino-4-phenyl-1,3-thiazol-5-yl)ethyl adamantane-1-carboxylate Chemical compound C1C(C2)CC(C3)CC2CC13C(=O)OC(C)C=1SC(N)=NC=1C1=CC=CC=C1 WOAKYNXITKJPIU-UHFFFAOYSA-N 0.000 description 2
- BPPBQXDRYMAPPZ-UHFFFAOYSA-N 2-[2-[[5-(2-acetyloxyethyl)-4-phenyl-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid Chemical compound CC(=O)OCCC=1SC(NC(=O)C=2N(C3=CC=CC=C3C=2)CC(O)=O)=NC=1C1=CC=CC=C1 BPPBQXDRYMAPPZ-UHFFFAOYSA-N 0.000 description 2
- QCNSLBGKXIACGC-UHFFFAOYSA-N 4-iodo-1-phenylbutan-1-one Chemical compound ICCCC(=O)C1=CC=CC=C1 QCNSLBGKXIACGC-UHFFFAOYSA-N 0.000 description 2
- OTCFHGIJKQWKTL-UHFFFAOYSA-N 5-(2-aminoethyl)-4-phenyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=CC=CC=2)=C1CCN OTCFHGIJKQWKTL-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 102000004859 Cholecystokinin Receptors Human genes 0.000 description 2
- 108090001085 Cholecystokinin Receptors Proteins 0.000 description 2
- 102000052874 Gastrin receptors Human genes 0.000 description 2
- 102100036016 Gastrin/cholecystokinin type B receptor Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N N,N′-Dicyclohexylcarbodiimide Substances C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 108010038988 Peptide Hormones Proteins 0.000 description 2
- 102000015731 Peptide Hormones Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000001414 amino alcohols Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 150000008365 aromatic ketones Chemical class 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- GBVAGZMJJSANDQ-UHFFFAOYSA-N benzyl 1h-indole-2-carboxylate Chemical compound C=1C2=CC=CC=C2NC=1C(=O)OCC1=CC=CC=C1 GBVAGZMJJSANDQ-UHFFFAOYSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- PBQBMNVQZCXYEU-UHFFFAOYSA-N ethyl 2-[2-[(1-acetylindole-2-carbonyl)amino]-4-(2,4-dimethoxyphenyl)-1,3-thiazol-5-yl]acetate Chemical compound CCOC(=O)CC=1SC(NC(=O)C=2N(C3=CC=CC=C3C=2)C(C)=O)=NC=1C1=CC=C(OC)C=C1OC PBQBMNVQZCXYEU-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 229960003857 proglumide Drugs 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 1
- CFFACCKCRJFEHF-UHFFFAOYSA-N 1-(2,4-dimethoxyphenyl)-3-phenylpropan-1-one Chemical compound COC1=CC(OC)=CC=C1C(=O)CCC1=CC=CC=C1 CFFACCKCRJFEHF-UHFFFAOYSA-N 0.000 description 1
- YIKFVXUBTZRUHZ-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]indole-2-carboxylic acid Chemical compound C1=CC=C2N(C(=O)OC(C)(C)C)C(C(O)=O)=CC2=C1 YIKFVXUBTZRUHZ-UHFFFAOYSA-N 0.000 description 1
- YUHQONKVKQCZRU-UHFFFAOYSA-N 1-phenylethanesulfonyl fluoride Chemical compound FS(=O)(=O)C(C)C1=CC=CC=C1 YUHQONKVKQCZRU-UHFFFAOYSA-N 0.000 description 1
- KEDLJDXOKLEMMD-UHFFFAOYSA-N 1-phenylmethoxycarbonylindole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=CC=CC=C2N1C(=O)OCC1=CC=CC=C1 KEDLJDXOKLEMMD-UHFFFAOYSA-N 0.000 description 1
- TYHYESDUJZRBKS-UHFFFAOYSA-N 2,3-dihydroindole-1-carboxylic acid Chemical compound C1=CC=C2N(C(=O)O)CCC2=C1 TYHYESDUJZRBKS-UHFFFAOYSA-N 0.000 description 1
- DVIIMIPZKGGFFF-UHFFFAOYSA-N 2-(2-amino-4-phenyl-1,3-thiazol-5-yl)ethanol Chemical compound S1C(N)=NC(C=2C=CC=CC=2)=C1CCO DVIIMIPZKGGFFF-UHFFFAOYSA-N 0.000 description 1
- DUDLNCUEDXJSME-UHFFFAOYSA-N 2-(4-oxo-4-phenylbutyl)isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCCC(=O)C1=CC=CC=C1 DUDLNCUEDXJSME-UHFFFAOYSA-N 0.000 description 1
- HGJXOJJNNNSWDC-UHFFFAOYSA-N 2-[2-(1h-indole-2-carbonylamino)-4-phenyl-1,3-thiazol-5-yl]ethyl acetate Chemical compound CC(=O)OCCC=1SC(NC(=O)C=2NC3=CC=CC=C3C=2)=NC=1C1=CC=CC=C1 HGJXOJJNNNSWDC-UHFFFAOYSA-N 0.000 description 1
- UYJIZDVXEHZOGT-UHFFFAOYSA-N 2-[2-(1h-indole-2-carbonylamino)-4-phenyl-1,3-thiazol-5-yl]ethyl n-phenylcarbamate Chemical compound S1C(NC(=O)C=2NC3=CC=CC=C3C=2)=NC(C=2C=CC=CC=2)=C1CCOC(=O)NC1=CC=CC=C1 UYJIZDVXEHZOGT-UHFFFAOYSA-N 0.000 description 1
- AVAMZDUOIUMFDQ-UHFFFAOYSA-N 2-[2-(2-amino-4-phenyl-1,3-thiazol-5-yl)ethyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCC=1SC(N)=NC=1C1=CC=CC=C1 AVAMZDUOIUMFDQ-UHFFFAOYSA-N 0.000 description 1
- HEKKXXFOGXARCW-UHFFFAOYSA-N 2-[4-(2,4-dimethoxyphenyl)-2-(1h-indole-2-carbonylamino)-1,3-thiazol-5-yl]acetic acid Chemical compound COC1=CC(OC)=CC=C1C1=C(CC(O)=O)SC(NC(=O)C=2NC3=CC=CC=C3C=2)=N1 HEKKXXFOGXARCW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- BGGPTORJZIJZOD-UHFFFAOYSA-N 2-bromo-1-(2,4-dimethoxyphenyl)-3-phenylpropan-1-one Chemical compound COC1=CC(OC)=CC=C1C(=O)C(Br)CC1=CC=CC=C1 BGGPTORJZIJZOD-UHFFFAOYSA-N 0.000 description 1
- AKLKIGMEFVPQFJ-UHFFFAOYSA-N 2-bromo-2-methoxy-1-phenylethanone Chemical compound COC(Br)C(=O)C1=CC=CC=C1 AKLKIGMEFVPQFJ-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- FECFPOSROULAEG-UHFFFAOYSA-N 4-phenyl-5-piperidin-1-yl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=CC=CC=2)=C1N1CCCCC1 FECFPOSROULAEG-UHFFFAOYSA-N 0.000 description 1
- XFDCNXIWKCIBAE-UHFFFAOYSA-N 5-bromo-1,3-thiazol-2-amine;hydrochloride Chemical compound Cl.NC1=NC=C(Br)S1 XFDCNXIWKCIBAE-UHFFFAOYSA-N 0.000 description 1
- ONHYSHQEAKQAFB-UHFFFAOYSA-N 5-bromo-4-phenyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=CC=CC=2)=C1Br ONHYSHQEAKQAFB-UHFFFAOYSA-N 0.000 description 1
- JMCITVCSEVUIAW-UHFFFAOYSA-N 5-methoxy-4-phenyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=CC=CC=2)=C1OC JMCITVCSEVUIAW-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- WLHBRQYVZLNQFE-UHFFFAOYSA-N O[S+]1C2=CC=CC=C2N=C1 Chemical compound O[S+]1C2=CC=CC=C2N=C1 WLHBRQYVZLNQFE-UHFFFAOYSA-N 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 210000004695 acinic cell Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 235000021229 appetite regulation Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-N bromoacetic acid Chemical compound OC(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 239000003743 cholecystokinin B receptor antagonist Substances 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- RLWOPORPWMDYMN-UHFFFAOYSA-N ethyl 2-[(1-acetylindole-2-carbonyl)amino]-4-phenyl-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(NC(=O)C=2N(C3=CC=CC=C3C=2)C(C)=O)=NC=1C1=CC=CC=C1 RLWOPORPWMDYMN-UHFFFAOYSA-N 0.000 description 1
- MHQBZHWOSGKSCB-UHFFFAOYSA-N ethyl 2-[2-amino-4-(2,4-dimethoxyphenyl)-1,3-thiazol-5-yl]acetate Chemical compound S1C(N)=NC(C=2C(=CC(OC)=CC=2)OC)=C1CC(=O)OCC MHQBZHWOSGKSCB-UHFFFAOYSA-N 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- UEALQOSQARFHSD-UHFFFAOYSA-N methyl 2-(2-amino-4-phenyl-1,3-thiazol-5-yl)acetate Chemical compound S1C(N)=NC(C=2C=CC=CC=2)=C1CC(=O)OC UEALQOSQARFHSD-UHFFFAOYSA-N 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- GILQNWCHYAFEOV-UHFFFAOYSA-N n-(4-phenyl-5-piperidin-1-yl-1,3-thiazol-2-yl)-1h-indole-2-carboxamide Chemical compound C=1C2=CC=CC=C2NC=1C(=O)NC(S1)=NC(C=2C=CC=CC=2)=C1N1CCCCC1 GILQNWCHYAFEOV-UHFFFAOYSA-N 0.000 description 1
- DISOQSUVUDKZLQ-UHFFFAOYSA-N n-(5-bromo-4-phenyl-1,3-thiazol-2-yl)-1h-indole-2-carboxamide Chemical compound BrC=1SC(NC(=O)C=2NC3=CC=CC=C3C=2)=NC=1C1=CC=CC=C1 DISOQSUVUDKZLQ-UHFFFAOYSA-N 0.000 description 1
- JCORXYSIEGJCKJ-UHFFFAOYSA-N n-(5-hydroxy-4-phenyl-1,3-thiazol-2-yl)-1h-indole-2-carboxamide Chemical compound OC=1SC(NC(=O)C=2NC3=CC=CC=C3C=2)=NC=1C1=CC=CC=C1 JCORXYSIEGJCKJ-UHFFFAOYSA-N 0.000 description 1
- BLDSDIKGDFXKJD-UHFFFAOYSA-N n-(5-methoxy-4-phenyl-1,3-thiazol-2-yl)-1h-indole-2-carboxamide Chemical compound COC=1SC(NC(=O)C=2NC3=CC=CC=C3C=2)=NC=1C1=CC=CC=C1 BLDSDIKGDFXKJD-UHFFFAOYSA-N 0.000 description 1
- FIVUELMTEICTHC-UHFFFAOYSA-N n-[2-(2-amino-4-phenyl-1,3-thiazol-5-yl)ethyl]acetamide Chemical compound S1C(N)=NC(C=2C=CC=CC=2)=C1CCNC(=O)C FIVUELMTEICTHC-UHFFFAOYSA-N 0.000 description 1
- LHRAWLRCSGEQOC-UHFFFAOYSA-N n-[5-benzyl-4-(2,4-dimethoxyphenyl)-1,3-thiazol-2-yl]-1h-indole-2-carboxamide Chemical compound COC1=CC(OC)=CC=C1C1=C(CC=2C=CC=CC=2)SC(NC(=O)C=2NC3=CC=CC=C3C=2)=N1 LHRAWLRCSGEQOC-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000926 not very toxic Toxicity 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- YSZIOXAEADAJLX-UHFFFAOYSA-N phthalazine-1,4-dione Chemical compound C1=CC=C2C(=O)N=NC(=O)C2=C1 YSZIOXAEADAJLX-UHFFFAOYSA-N 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- LEWDKQKVAFOMPI-UHFFFAOYSA-N quinoline-4-carboxamide Chemical class C1=CC=C2C(C(=O)N)=CC=NC2=C1 LEWDKQKVAFOMPI-UHFFFAOYSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- SANBIBGFRRCPOZ-UHFFFAOYSA-N tert-butyl 2-[2-[[5-(2-acetyloxyethyl)-4-phenyl-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetate Chemical compound CC(=O)OCCC=1SC(NC(=O)C=2N(C3=CC=CC=C3C=2)CC(=O)OC(C)(C)C)=NC=1C1=CC=CC=C1 SANBIBGFRRCPOZ-UHFFFAOYSA-N 0.000 description 1
- XCTWTDDJJOPQRI-UHFFFAOYSA-N tert-butyl 2-[2-[[5-(2-hydroxyethyl)-4-phenyl-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetate Chemical compound C(C)(C)(C)OC(=O)CN1C(=CC2=CC=CC=C12)C(=O)NC=1SC(=C(N1)C1=CC=CC=C1)CCO XCTWTDDJJOPQRI-UHFFFAOYSA-N 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- MFPWEWYKQYMWRO-UHFFFAOYSA-N tert-butyl carboxy carbonate Chemical compound CC(C)(C)OC(=O)OC(O)=O MFPWEWYKQYMWRO-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/18—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9106814A FR2677356B1 (fr) | 1991-06-05 | 1991-06-05 | Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO922215D0 NO922215D0 (no) | 1992-06-04 |
| NO922215L NO922215L (no) | 1992-12-07 |
| NO300135B1 true NO300135B1 (no) | 1997-04-14 |
Family
ID=9413505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO922215A NO300135B1 (no) | 1991-06-05 | 1992-06-04 | Heterocyklisk substituerte 2-acylamino-5-tiazoler, og mellomprodukter for fremstilling derav |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US5314889A (cs) |
| EP (1) | EP0518731B1 (cs) |
| JP (1) | JP3199451B2 (cs) |
| KR (1) | KR100222309B1 (cs) |
| AT (1) | ATE170186T1 (cs) |
| AU (1) | AU650754B2 (cs) |
| BR (2) | BR9202156A (cs) |
| CA (1) | CA2070526A1 (cs) |
| CZ (1) | CZ289003B6 (cs) |
| DE (1) | DE69226729T2 (cs) |
| ES (1) | ES2121575T3 (cs) |
| FI (1) | FI922589A7 (cs) |
| FR (1) | FR2677356B1 (cs) |
| HU (1) | HU221312B1 (cs) |
| IE (1) | IE921814A1 (cs) |
| IL (1) | IL102004A (cs) |
| MX (1) | MX9202662A (cs) |
| NO (1) | NO300135B1 (cs) |
| NZ (1) | NZ243009A (cs) |
| RU (1) | RU2059637C1 (cs) |
| TW (1) | TW202448B (cs) |
| UA (1) | UA26899C2 (cs) |
| ZA (1) | ZA923981B (cs) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4303676A1 (de) * | 1993-02-09 | 1994-08-11 | Bayer Ag | 1-Aryltriazolin(thi)one |
| FR2701708B1 (fr) * | 1993-02-19 | 1995-05-19 | Sanofi Elf | Dérivés de 2-amido-4-phénylthiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament. |
| FR2703995B1 (fr) * | 1993-04-16 | 1995-07-21 | Sanofi Elf | 5-acylamino 1,2,4-thiadiazoles, leur preparation et compositions pharmaceutiques en contenant. |
| WO1995032963A1 (en) * | 1994-06-01 | 1995-12-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienylazole compound and thienotriazolodiazepine compound |
| MX9604483A (es) * | 1994-09-08 | 1998-02-28 | Jean-Francois Rossignol | Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas. |
| NZ333382A (en) * | 1996-06-27 | 2000-05-26 | Janssen Pharmaceutica Nv | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines |
| WO1998035707A1 (en) | 1997-02-18 | 1998-08-20 | Thomas Jefferson University | Compositions that bind to pancreatic cancer cells and methods of using the same |
| FR2768737B1 (fr) * | 1997-09-19 | 2000-05-19 | Sanofi Sa | Derives de carboxamidothiazoles, leur preparation, les compositions pharmaceutiques en contenant |
| CO4970713A1 (es) * | 1997-09-19 | 2000-11-07 | Sanofi Synthelabo | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen |
| GB0028383D0 (en) * | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| US7169931B2 (en) * | 2001-01-26 | 2007-01-30 | Shionogi & Co., Ltd. | Cyclic compounds exhibiting thrombopoietin receptor agonism |
| US20040077697A1 (en) * | 2001-02-02 | 2004-04-22 | Hiroyuki Koshio | 2-Acylaminothiazole derivative or its salt |
| ES2610611T3 (es) * | 2002-01-18 | 2017-04-28 | Astellas Pharma Inc. | Derivado de 2-acilaminotiazol o sal del mismo |
| US20030225054A1 (en) * | 2002-06-03 | 2003-12-04 | Jingwu Duan | Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents |
| FR2854158B1 (fr) * | 2003-04-25 | 2006-11-17 | Sanofi Synthelabo | Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique |
| MXPA06000441A (es) * | 2003-07-17 | 2006-04-05 | Astellas Pharma Inc | Derivado de 2-acilaminotiazole o sal del mismo. |
| SA04250288B1 (ar) * | 2003-09-19 | 2008-07-19 | سولفاي فارماسوتيكالز بي . في | مشتقات ثيازول thiazole كمعدلات لمستقبل المكونات الكيميائية للقنب cannabinoid |
| JP4527729B2 (ja) * | 2003-12-08 | 2010-08-18 | エフ．ホフマン−ラ ロシュ アーゲー | 新規チアゾール誘導体 |
| BRPI0418082B8 (pt) | 2003-12-26 | 2021-05-25 | Kyowa Hakko Kirin Co Ltd | derivados de tiazol úteis como antagonistas de receptor de adenosina a2a |
| GB0401336D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| CA2567813C (en) | 2004-05-23 | 2015-11-24 | Gerard M. Housey | Theramutein modulators |
| FR2872813B1 (fr) * | 2004-07-09 | 2007-01-19 | Sanofi Synthelabo | Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique |
| ES2401138T3 (es) * | 2004-08-13 | 2013-04-17 | Genentech, Inc. | Inhibidores basados en tiazol de enzimas que usan ATP |
| FR2876692B1 (fr) * | 2004-10-19 | 2007-02-23 | Sanofi Aventis Sa | Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique |
| JP4774995B2 (ja) * | 2005-01-12 | 2011-09-21 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 |
| AU2006343359A1 (en) * | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| EP1894930A4 (en) | 2005-06-23 | 2010-06-23 | Kyowa Hakko Kirin Co Ltd | THIAZOLE DERIVATIVE |
| ES2643340T3 (es) | 2005-08-02 | 2017-11-22 | Kyowa Hakko Kirin Co., Ltd. | Agentes para tratar y/o prevenir trastornos del sueño |
| WO2007054783A2 (en) * | 2005-11-08 | 2007-05-18 | Astellas Pharma Inc. | Compositions and methods for treating thrombocytopenia |
| FR2895989B1 (fr) * | 2006-01-06 | 2010-04-30 | Sanofi Aventis | Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique |
| TWI444370B (zh) * | 2006-01-25 | 2014-07-11 | Synta Pharmaceuticals Corp | 用於發炎及免疫相關用途之噻唑及噻二唑化合物 |
| CN101096363B (zh) * | 2006-06-27 | 2011-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途 |
| AU2007284644B2 (en) * | 2006-08-08 | 2011-09-01 | Akarx, Inc. | Compositions and methods for increasing blood platelet levels in humans |
| JP2011509261A (ja) * | 2008-01-07 | 2011-03-24 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連用途向けの化合物 |
| BRPI0910346A2 (pt) | 2008-03-31 | 2015-10-06 | Hoffmann La Roche | compostos de benzopirano e benzoxapina inibidores de pi3k e métodos de uso |
| JP2013501811A (ja) * | 2009-08-14 | 2013-01-17 | エーザイ インコーポレーテッド | 血小板産生を刺激するためのｅ５５０１の使用 |
| AU2010299816C1 (en) | 2009-09-28 | 2018-02-01 | F. Hoffmann-La Roche Ag | Benzoxazepin PI3K inhibitor compounds and methods of use |
| PH12012500608A1 (en) * | 2009-09-28 | 2017-08-09 | Hoffmann La Roche | Benzoxepin pi3k inhibitor compounds and methods of use |
| CA2793311C (en) * | 2010-03-17 | 2019-01-15 | Taivex Therapeutics Inc. | Modulators of hec1 activity and methods therefor |
| EP2688891B1 (en) | 2011-03-21 | 2017-11-15 | F. Hoffmann-La Roche AG | Benzoxazepin compounds selective for pi3k p110 delta and methods of use |
| AR089999A1 (es) | 2012-02-17 | 2014-10-01 | Hoffmann La Roche | Compuestos triciclicos y metodos para el uso de los mismos |
| CN113164419A (zh) | 2018-09-07 | 2021-07-23 | 皮克医疗公司 | Eif4e抑制剂和其用途 |
| EP4114529A1 (en) | 2020-03-03 | 2023-01-11 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| JP2024534127A (ja) | 2021-08-25 | 2024-09-18 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
| JP2024532276A (ja) | 2021-08-25 | 2024-09-05 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3210368A (en) * | 1964-09-29 | 1965-10-05 | Ciba Geigy Corp | Certain 2-amino-4-aryl-5-n, n-disubstituted amino-lower alkyl-thiazole compounds |
| DE3681358D1 (de) * | 1985-07-09 | 1991-10-17 | Pfizer | Substituierte oxindol-3-carboxamine als entzuendungshemmendes und schmerzstillendes mittel. |
| DE3705934A1 (de) * | 1987-02-25 | 1988-09-08 | Nattermann A & Cie | Indolyl-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US4971978A (en) * | 1987-09-21 | 1990-11-20 | Nadzan Alex M | Derivatives of D-glutamic acid and D-aspartic acid |
| WO1989005812A1 (fr) * | 1987-12-22 | 1989-06-29 | Yoshitomi Pharmaceutical Industries, Ltd. | Composes de thienodiazepine et leur utilisation en medecine |
| IE68593B1 (en) * | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
-
1991
- 1991-06-05 FR FR9106814A patent/FR2677356B1/fr not_active Expired - Fee Related
-
1992
- 1992-05-26 IL IL102004A patent/IL102004A/xx not_active IP Right Cessation
- 1992-05-28 AU AU17279/92A patent/AU650754B2/en not_active Ceased
- 1992-05-29 US US07/889,910 patent/US5314889A/en not_active Expired - Fee Related
- 1992-06-01 TW TW081104270A patent/TW202448B/zh active
- 1992-06-01 ZA ZA923981A patent/ZA923981B/xx unknown
- 1992-06-03 ES ES92401518T patent/ES2121575T3/es not_active Expired - Lifetime
- 1992-06-03 EP EP92401518A patent/EP0518731B1/fr not_active Expired - Lifetime
- 1992-06-03 NZ NZ243009A patent/NZ243009A/en unknown
- 1992-06-03 DE DE69226729T patent/DE69226729T2/de not_active Expired - Fee Related
- 1992-06-03 AT AT92401518T patent/ATE170186T1/de not_active IP Right Cessation
- 1992-06-04 NO NO922215A patent/NO300135B1/no not_active IP Right Cessation
- 1992-06-04 CZ CS19921693A patent/CZ289003B6/cs not_active IP Right Cessation
- 1992-06-04 JP JP14415092A patent/JP3199451B2/ja not_active Expired - Fee Related
- 1992-06-04 HU HU9201870A patent/HU221312B1/hu not_active IP Right Cessation
- 1992-06-04 CA CA002070526A patent/CA2070526A1/en not_active Abandoned
- 1992-06-04 FI FI922589A patent/FI922589A7/fi not_active Application Discontinuation
- 1992-06-04 RU SU5011874/04A patent/RU2059637C1/ru not_active IP Right Cessation
- 1992-06-04 MX MX9202662A patent/MX9202662A/es not_active IP Right Cessation
- 1992-06-05 KR KR1019920009859A patent/KR100222309B1/ko not_active Expired - Fee Related
- 1992-06-05 BR BR929202156A patent/BR9202156A/pt not_active Application Discontinuation
- 1992-07-01 IE IE181492A patent/IE921814A1/en not_active IP Right Cessation
-
1993
- 1993-06-15 UA UA93002939A patent/UA26899C2/uk unknown
-
1994
- 1994-03-03 US US08/205,408 patent/US5380736A/en not_active Expired - Fee Related
-
1997
- 1997-05-12 BR BR1100786-9A patent/BR1100786A/pt active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO300135B1 (no) | Heterocyklisk substituerte 2-acylamino-5-tiazoler, og mellomprodukter for fremstilling derav | |
| KR0147281B1 (ko) | 헤테로사이클릭 치환된 아실아미노티아졸 그 제조방법 및 그 화합물을 포함하는 약학적 조성물 | |
| US6380230B1 (en) | Carboxamidothiazole derivatives, preparation, pharmaceutical compositions containing them | |
| AU644054B2 (en) | Benzoisothiazole and benzoisoxazole-3-carboxamides | |
| NO310619B1 (no) | Acetamidderivater og farmasöytisk preparat inneholdende disse | |
| RU2125569C1 (ru) | Производные полизамещенных 2-амидо-4-фенилтиазолов, способ их получения, промежуточные соединения синтеза и фармацевтическая композиция на их основе | |
| KR930011038B1 (ko) | 테트라하이드로 벤즈이미다졸 유도체 및 이의 제조방법 | |
| IE811112L (en) | Derivatives of 4-hydroxy-3-quinoline carboxylic acid | |
| JPH06340663A (ja) | ５−アシルアミノ−１，２，４−チアジアゾール、その製造法およびそれを含有する医薬組成物 | |
| JPH08506337A (ja) | 抗精神活性を有するヘテロ芳香族化合物 | |
| Wu et al. | Discovery, synthesis, and biological mechanism evaluation of novel quinoline derivatives as potent NLRP3 inhibitors | |
| GB1569238A (en) | 2,5-dihdro-1,2-thiazino(5,6-b)indol-3-carboxamide-1,1-dioxide derivatives | |
| RU2059623C1 (ru) | Тетрагидробензимидазольное производное или его фармацевтически приемлемая соль и фармацевтическая композиция на его основе, проявляющая активность 5-ht3-антагониста | |
| DK165789B (da) | 4-oxo-4h-pyrimidooe2,1,aaaisoquinolinderivater, analogifremgangsmaade til fremstilling deraf, farmaceutisk praeparat indeholdende disse samt derivaterne til anvendelse som antiallergisk middel | |
| US4563453A (en) | Thiazine derivatives, processes for preparation thereof and pharmaceutical composition comprising the same | |
| JP2003335670A (ja) | 癒着防止剤 | |
| CZ2000977A3 (cs) | Karboxamidothiazolové deriváty, způsob jejich přípravy a farmaceutické prostředky s jejich obsahem | |
| JPS63301881A (ja) | インドリルピペリジン誘導体 | |
| HK1012397B (en) | 2-(indol-2-yl-carbonylamino)-thiazole derivatives, their preparation and pharmaceutical compositions containing them | |
| FR2777887A1 (fr) | Derives de carboxamidothiazoles, leur preparation, les compositions pharmaceutiques en contenant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |